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Novelty and Impact 
Associations between body mass index (BMI) and several cancers are well established. 
However, the causal relationship of BMI on lung cancer is contradictory among studies. 
Here, using univariable and multivariable Mendelian randomization (MR), we confirmed 
an inverse direct effect of BMI on lung adenocarcinoma and a direct causal effect on 
small cell lung cancer, but did not observe direct effect of BMI on lung squamous cell 




At the time of cancer diagnosis, body mass index (BMI) is inversely correlated with lung 
cancer risk, which may reflect reverse causality and confounding due to smoking 
behavior. We used two-sample univariable and multivariable Mendelian randomization 
(MR) to estimate causal relationships of BMI and smoking behaviors on lung cancer and 
histological subtypes, based on an aggregated genome wide association studies 
(GWASs) analysis of lung cancer in 29,266 cases and 56,450 controls. We observed a 
positive causal effect for high BMI on occurrence of small cell lung cancer (odds ratio 
(OR) = 1.60, 95% confidence interval (CI) = 1.24-2.06, P = 2.70 x 10-4). After adjustment 
of smoking behaviors using multivariable Mendelian randomization (MVMR), a direct 
causal effect on small cell lung cancer (ORMVMR = 1.28, 95% CI = 1.06-1.55, PMVMR = 
0.011), and an inverse effect on lung adenocarcinoma (ORMVMR = 0.86, 95% CI = 0.77-
0.96, PMVMR = 0.008) were observed. A weak increased risk of lung squamous cell 
carcinoma was observed for higher BMI in univariable Mendelian randomization 
(UVMR) analysis (ORUVMR = 1.19, 95% CI = 1.01-1.40, PUVMR = 0.036), but this effect 
disappeared after adjustment of smoking (ORMVMR = 1.02, 95% CI = 0.90-1.16, PMVMR = 
0.746). These results highlight the histology-specific impact of BMI on lung 
carcinogenesis and imply mediator role of smoking behaviors in the association 
between BMI and lung cancer.  
Introduction 
Although body mass index (BMI) is known to be associated with the risk of several 
cancers1, many epidemiological studies1-6 have found that BMI is inversely correlated 
with lung cancer risk. At the time of or 1 to 2 year leading up to cancer diagnosis, lung 
cancer cases tend to have lower BMI compared to age, population, and sex matched 
controls7. This observation may reflect reverse causality related to the latent effects of 
lung cancer on BMI due to cachexia and the disease process8 and confounding due to 
smoking behavior4, 9-11, which suppresses appetite. 
Mendelian randomization (MR) complements traditional epidemiological methods as 
it uses genetic variants as instrumental variables (IVs) to estimate causal effects and is 
free from the effects of confounders and reverse causality12 but could be influenced by 
pleiotropy or linkage disequilibrium among the markers13. The conventional, univariable 
MR analysis evaluates the effect of a single predictor on an outcome. There are three 
assumptions for a valid IV – it must be: (i) associated with the exposure (the “relevance” 
assumption); (ii) independent of the outcome given the exposure (the “exclusion 
restriction”); and (iii) independent of all (both observed and unobserved) confounders 
(the “exchangeability” assumption).14, 15 If an IV is associated with a confounder of 
exposure and outcome then there is a conflict with these assumptions, which may lead 
to potential biases and erroneous conclusions. If associations between the IV and both 
the exposure and the confounder are measured, then their effects on the outcome can 
be estimated jointly using multivariable MR16. 
Multivariable MR is an extension of univariable MR that takes pleiotropy among 
multiple traits into account. The assumptions of multivariable MR is broader than that of 
univariable MR: genetic variants could influence multiple measured exposures, and the 
exclusion restriction and exchangeability assumption extend accordingly.16 Under the 
scenario that there is a secondary exposure acts as a mediator of the relationship 
between primary exposure and outcome, multivariable MR can provide a consistent 
estimator of the direct effect of the exposure on the outcome that does not work via the 
mediator.17 
In this study, we performed Mendelian randomization analyses to investigate causal 
effects of BMI and smoking phenotypes on lung cancer using univariable MR and 
multivariable MR methods. Sensitivity analyses were conducted to evaluate the impact 
that assumptions had on the findings and to ensure the robustness of the results. 
 
Materials and Methods 
Genetic instruments for BMI and smoking phenotypes 
Genetic instruments for BMI were identified using results from the largest available 
meta-analysis of genome wide association studies (GWASs) for BMI, which combined 
summary statistics from the Genetic Investigation of ANthropometric Traits (GIANT) 
consortium18 with GWAS for BMI performed in UK Biobank participants of European 
ancestry, reaching about 700,000 individuals.19 The former association testing was 
performed with the inverse normally transformed BMI residuals using linear regression 
assuming an additive genetic model. The associations identified in the latter study were 
estimated using linear mixed model assuming an infinitesimal model. METAL20 was 
used to perform fixed-effect inverse variance weighted meta-analysis. 
Genetic instruments for smoking phenotypes were obtained from the most recent 
meta-analysis on tobacco and alcohol consumption based on over 30 GWASs, which 
identified 566 genetic variants associated with four smoking phenotypes in over 1.2 
million individuals of European ancestry.21 Detailed information about the smoking 
phenotypes have been described elsewhere21. Briefly, they included smoking status 
(Ever/Never), age of smoking initiation, smoking cessation (Current/Former), and 
number of cigarettes smoked per day (either as a current smoker or former smoker, 
quantitative measures were binned into five bins or collected with pre-defined bins as 
follows: 1 = 1-5, 2 = 6-15, 3 = 16-25, 4 = 26-35, 5 = 36+ cigarettes per day). The 
association statistics were generated using a linear mixed model for all phenotypes in 
family studies and quasi-continuous phenotypes (age of smoking initiation and 
cigarettes per day) in unrelated individuals. A logistic model was utilized to estimate 
additive genetic effects for binary phenotypes (smoking status and smoking cessation) 
in studies of unrelated individuals. Meta-analysis was performed using rareGWAMA22. 
The IVs for MR anayses were selected based on the following criteria: (i) r2 measure 
of linkage disequilibrium (LD) among instruments < 0.01 at a 10Mb window; (ii) P value 
less than the genome-wide significant level identified in the corresponding study (1 x 10-
8 for BMI, 5 x 10-8 for smoking phenotypes); (iii) minor allele frequency (MAF) > 0.01; 
(iv) non-palindromic single nucleotide polymorphisms (SNPs) (A/T and G/C 
polymorphisms were considered for removal but there was no ambiguity in effects). We 
further split the genetic instruments for BMI into those that only affect BMI (“BMI-Only 
SNP”) and those that affect both smoking and BMI (“BMI&Smoking SNP”) by using the 
P values in the tobacco use GWAS meta-analysis: If the P value of any of smoking 
phenotypes was less than 0.05, it was classified as the “BMI&Smoking SNP”. 
 
Genetic associations of SNPs with lung cancer risk 
Summary statistics on lung cancer risk, including odds ratio (OR) estimates and 
standard errors for instrumental SNPs, were available from the Transdisciplinary 
Research in Cancer of the Lung (TRICL) and International Lung Cancer Consortium 
(ILCCO) based on an aggregated GWAS analysis of lung cancer in 29,266 cases and 
56,450 controls.23 The associations between instrumental SNPs and histological 
subtypes of lung cancer were also provided in the original study. These analyses were 




The relationship between BMI, smoking, and lung cancer is illustrated in Figure 1. The 
direct effect of BMI on lung cancer is the effect that not via smoking, which is equal to 
βXZ. The total effect of BMI on lung cancer is the effect of BMI on lung cancer directly 
plus the effect of BMI on lung cancer via smoking, which is equal to βXZ + αXYβYZ. We 
performed univariable MR analyses for BMI and smoking on lung cancer risk separately 
to estimate the total causal effects of BMI on lung cancer and smoking behaviors on 
lung cancer. To evaluate whether BMI was causal for smoking phenotypes or smoking 
phenotypes have causal effects on BMI, we conducted bidirectional MR for BMI and 
smoking phenotypes. Specifically, MR analyses were first performed from BMI to 
smoking phenotypes, and then the direction was reversed. 
To investigate the direct effects of BMI and smoking behaviors on lung cancer, we 
performed multivariable MR16 analysis, which is an extension of univariable MR that 
allows detecting causal effects of multiple risk factors jointly.17 Multivariable MR takes 
into account the relationship between BMI and smoking phenotypes and the fact that 
the SNPs used in the MR analyses are often associated with both BMI and smoking (i.e. 
SNPs in our analyses were associated with BMI and at least one smoking phenotype 
with P < 0.05, the “BMI&Smoking SNP”). The SNPs used to conduct multivariable MR 
were combinations of instrumental variables of each exposure. We restricted the 
analysis to SNPs that were clumped on r2 < 0.01 within 10Mb. MR analyses and 
clumping were conducted using the packages “TwoSampleMR”24 and 
“MendelianRandomization” (https://cran.r-
project.org/package=MendelianRandomization) in R. 
 
Sensitivity analysis 
We applied several MR methods to perform MR analyses. For univariable MR, we used 
inverse-variance weighted (IVW)25, 26, weighted median27, weighted mode28, and MR-
Egger13 approaches. For multivariable MR, we used regression-based IVW16 and 
Egger29. We calculated R2 to estimate the proportion of phenotypic variance explained 
and F-statistics to evaluate the strength of instruments30. The two-sample conditional F-
statistics (FTS)17, 31 were also estimated to evaluate the strength of SNP-exposure 
conditional on other exposures. The intercept test of MR-Egger was used to assess 
horizontal pleiotropic effects, IGX2 statistic to check the violation of “NOME (NO 
Measurement Error) assumption”, which states the potential relative bias due to 
measurement error. The heterogeneity estimated by Cochran’s Q test was to appraise 
whether any single instrumental variable was driving the results and to check for 
consistency of the analyses with MR assumptions. The outliers in IVW and MR-Egger 
regression models was identified using RadialMR32. In addition, we calculated the 




In total, 842 independent SNPs were included as instrumental variables for BMI and 
110, 7, 10, and 29 SNPs for smoking phenotypes of smoking status, age of smoking 
initiation, smoking cessation, and cigarettes per day, respectively (Supporting 
Information Table S1). The F-statistic values (Supporting Information Table S2) for 
individual SNPs ranged from 30 to 1360, with means of 64, 41, 39, 53, and 92 for BMI, 
smoking status, age of smoking initiation, smoking cessation, and cigarettes per day, 
respectively. However, the two-sample conditional F-statistics were all less than 10 for 
BMI and all smoking phenotypes, indicating the strength of genetic instruments was 
significantly lower after conditioning on other exposures, which may result in greatly 
reduced power for multivariavle MR to estimate causal effects. Despite a reduction in 
strength, the BMI instrument had an FTS over 8 reflecting moderate strength31. The 
variability explained by these genetic instruments were 7.33% for BMI, 0.71% for 
smoking status, 0.1% for age of smoking initiation, 0.17% for smoking cessation, and 
1.03% for cigarettes per day(Supporting Information Table S2). Power calculations for 
the univariable IVW MR analyses (Supporting Information Figure S1) indicated greater 
than 80% statistical power to detect an odds ratio bigger than 1.077 for per 1 unit 
increase of BMI, 1.26 for ever smoking, 1.77 for one age younger of smoking initiation, 
1.57 for current smoking, and 1.213 for per 10 cigarettes increase of cigarettes per day. 
There were 451 instrumental variables for BMI identified as “BMI&Smoking SNP” and 
390 identifed as “BMI-Only SNP” (Supporting Information Table S1). 
 
Univariable MR analyses 
From the univariable MR analyses (Table 1, Supporting Information Table S3 and 
Figure S2) we observed that increased BMI has a positive effect on occurrence of 
overall lung cancer when using all BMI associated SNPs (OR = 1.19, 95% confidence 
interval (CI) = 1.10-1.28, P = 7.24 x 10-6). This effect was also significant in histological 
subtypes of lung squamous cell carcinoma (OR = 1.36, 95% CI = 1.22-1.52, P = 3.59 x 
10-8) and small cell lung cancer (OR = 1.73, 95% CI = 1.47-2.04, P = 5.50 x 10-11) but 
not in lung adenocarcinoma (OR = 1.00, 95% CI = 0.91-1.10, P =0.935) (the first four 
rows of Table 1). The causal relationships estimated by BMI&Smoking SNP were 
consistent with the all SNPs set, with a slightly stronger effect (the 5-8 rows of Table 1). 
The BMI-Only SNP IVs were significant for small cell lung cancer (OR = 1.60, 95% CI = 
1.24-2.06, P = 2.70 x 10-4); the associations between BMI and other lung cancer 
subtypes were weak or nonexistent (the last four rows of Table 1). As smoking 
behaviors are confounders of BMI and lung cancer, the BMI-Only SNPs, which have 
excluded genetic variants that have significant association with smoking phenotypes, 
should be instruments that are more valid for BMI in univariable MR analysis. The 
univariable MR using BMI-Only SNP estimates the total effect of BMI on lung cancer.17 
Among the four smoking phenotypes (Supporting Information Table S4 and Figure 
S3), smoking status was positively associated with lung cancer and histological 
subtypes, which is consistent with known associations of smoking with lung cancer risk. 
Age of smoking initiation was inversely associated with lung squamous cell carcinoma 
and small cell lung cancer, which indicated that the earlier an individual started regular 
smoking, the greater his/her risk of lung squamous cell carcinoma and small cell lung 
cancer. There was an expected strong evidence of causal effects of cigarettes per day 
(per 10 cigarettes increase) with lung cancer and histological subtypes (Overall: OR = 
2.89, 95% CI = 2.33-3.58, P = 3.59 x 10-22; Adenocarcinoma: OR = 2.57, 95% CI = 
2.06-3.20, P = 6.20 x 10-17; Squamous cell: OR = 3.27, 95% CI = 2.60-4.10, P = 1.66 x 
10-24; Small cell: OR = 3.32, 95% CI = 2.52-4.37, P = 1.80 x 10-17). No significant causal 
effects of the genetic instrument modeling smoking cessation on lung cancer was 
observed. The sensitivity analyses using median weighted IVs was similar for all 
exposures (ORs were comparable to those estimated by the IVW method), except for 
smoking cessation. Results for MR Egger regression were also qualitatively similar to 
results estimated by the IVW method, except smoking cessation for which protective 
effects were found (Supporting Information Table S4 and Figure S3). These results 
suggest heterogeneity in instrumental effects for the smoking cessation variable but not 
for other variables.  
The MR analyses for evaluating the effect of BMI on smoking phenotypes yielded 
consistent results across three SNP sets (Supporting Information Table S5 and Figure 
S4). Increased BMI has positive effects on smoking status (OR = 1.24, 95% CI = 1.19-
1.28, P = 6.60 x 10-36), smoking cessation (OR = 1.14, 95% CI = 1.11-1.18, P = 7.20 x 
10-15), and cigarettes per day (OR = 1.39, 95% CI = 1.34-1.44, P = 7.54 x 10-64), while 
inverse effect on age of smoking initiation (OR = 0.91, 95% CI = 0.90-0.93, P = 3.68 x 
10-26). There was limited evidence (Supporting Information Table S5 and Figure S5) for 
effects of smoking behaviors on BMI. In addition, no significant horizontal pleiotropic 
effects were detected in MR Egger (for the intercept of MR Egger, all P value more than 
0.1). The low IGX2 statistics (less than 80%) for all smoking phenotypes suggest bias 
due to measurement errors in MR Egger (the last four rows of Supporting Information 
Table S5). 
 
Multivariable MR analyses 
We estimated mutually the effects of smoking and BMI on lung cancer using 
multivariable MR and observed a directly inverse effect of BMI on lung adenocarcinoma 
(OR = 0.86, 95% CI = 0.77-0.96, P = 0.008) and a weak risk effect on small cell lung 
cancer (OR = 1.28, 95% CI = 1.06-1.55, P = 0.011) (Table 2 and Figure 2). After 
adjustment of BMI and other smoking phenotypes, smoking status still had a direct 
effect on overall lung cancer, lung adenocarcinoma and lung squamous cell carcinoma, 
but not on small cell lung cancer. There were positive direct effects of smoking 
cessation on overall lung cancer, squamous and small cell lung cancer, but no direct 
effect on lung adenocarcinoma. Cigarettes per day has direct effects on overall lung 
cancer, squamous and small cell lung cancer. No significant direct effect was detected 
for age of smoking initiation on lung cancer risk, while jointly modeling BMI and other 
smoking phenotypes. 
We also investigated the direct effects between BMI and smoking behaviors using 
multivariable MR (Supporting Information Table S6 and Table S7). Strong evidence for 
direct effects of BMI on smoking status and cigarettes per day were observed, as well 
as inverse effect on age of smoking initiation. There was also some evidence for direct 
effects of smoking behaviors on BMI, such as smoking status, smoking cessation and 
cigarettes per day. 
 
Sensitivity analysis 
Since genome-wide significant level for each exposure was determined according to the 
corresponding study of its genetic instruments19, 21, the thresholds used for BMI (1 x 10-
8) and smoking phenotypes (5 x 10-8) were different. To provide a sensitivity analysis, 
we selected IVs based on instruments satisfying either 5 x 10-8 or 1 x 10-8 and 
performed additional MR analyses. As shown in Supporting Information Table S8-S10, 
the causal effects of BMI and smoking behaviors on lung cancer were robust using 
different thresholds. 
In univariable MR analyses, the IGX2 statistics of MR Egger for BMI and smoking 
phenotypes on lung cancer (Supporting Information Table S3 and Table S4) were less 
than 90%, except that of cigarettes per day on lung cancer and its subtypes (range from 
96.2% to 96.5%). The lower values of IGX2 indicates violation of the “NOME” assumption 
in the causal estimates due to variations in the genetic associations. In addition, the 
Cochran’s Q test in the IVW model and MR Egger model (Supporting Information Table 
S11) suggested that there was strong evidence of heterogeneity in most of the 
instrumental variables. However, we did not observe significant directional pleiotropy 
using MR Egger, as the P value for the intercept tests were not significant (Supporting 
Information Table S3 and Table S4), which suggests balanced pleiotropy13 in the 
genetic instruments of univariable MR analyses. Balanced pleiotropy means that the 
pleiotropic effects of genetic instruments are balanced around the overall effect. The 
symmetry in the funnel plots also supported balanced pleiotropy (Supporting Information 
Figure S6-S7). However, outliers in the scatter plot suggested presence of 
heterogeneity. (Supporting Information Figure S8-S9). The outliers in the analysis of 
univariable MR for smoking cessation on lung cancer risk were rs518425 (intronic of 
CHRNA5) and rs56113850 (intronic of CYP2A6). The effects of these two large-effect 
SNPs appear to be opposite for BMI phenotypes, which explains the symmetry. After 
removing these two SNPs, no heterogeneity for smoking cessation remained and the 
causal relationship between smoking cessation and lung cancer was significant 
(Supporting Information Table S12 and Figure S10). In addition, the estimates of MR 
IVW, MR Weighted Median, MR Weighted Mode, and MR Egger show nearly consistent 
effects except for smoking cessation, which has strong evidence of heterogeneity 
(Supporting Information Figure S2-S5). 
The estimates were robust between multivariable MR IVW and multivariable MR 
Egger analyses, which suggested reliable evaluation of causal effects for BMI and 
smoking phenotypes on lung cancer risk (Table 2, Figure 2 and Supporting Information 
Figure S11). In addition, there was no significant evidence for a non-zero intercept of 
multivariable MR Egger regression, which also supports the reliability of the results for 
multivariable MR analyses. 
 
MR analyses for lung cancer among ever-/never-smokers 
To investigate the role of smoking phenotypes in the causal relationship between BMI 
and lung cancer, we further performed MR analyses for BMI and smoking phenotypes 
on ever- versus never-smokers for lung cancer. A positive effect of high BMI on 
occurrence of lung cancer among ever-smokers was observed using BMI-All SNPs or 
BMI&Smoking SNPs. An inverse effect of BMI on risk for lung cancer among never-
smokers was identified using BMI-Only SNPs (Supporting Information Table S13). After 
adjustment of smoking phenotypes using multivariable MR, the estimated casual effects 
of BMI on ever- or never-smokers lung cancer was further attenuated (Supporting 
Information Table S14). A weakly but not significant protective effect of BMI on lung 
cancer risk among never smokers was observed, but further much larger studies are 
needed to evaluate these associations. 
 
Discussion 
In this study, we observed that adjusted for smoking, BMI decreased risk of lung 
adenocarcinoma and increased risk of small cell lung cancer. BMI increased risk of lung 
squamous cell carcinoma but this effect was mediated by smoking. This study also 
highlights the effectiveness and necessity of multivariable MR in MR analyses, 
especially when large amounts of genetic variants are used as instrumental variables. 
Some previous observational studies5, 6, 34-37 have demonstrated that BMI was 
associated with decreasing risk of lung cancer, even after adjustment for smoking and 
other confounders5, but separating out residual confounding with smoking is difficult in 
observational analyses. The inverse association for lung adenocarcinoma and positive 
association for small cell carcinoma were also observed in a prospective cohort study6. 
There was no heterogeneity between males and females, but the association was 
stronger in ever-smokers than in never-smokers6, 34, 35. In our findings, there was 
evidence of a causal effect for overall lung cancer among ever-smokers if using the 
SNPs associated with both BMI and smoking behavior, while reverse effect for overall 
lung cancer among never-smokers if using the SNPs only associated with BMI, 
suggests there might be some interactions between smoking phenotypes and BMI in 
the process of impacting lung carcinogenesis. 
Carreras-Torres et al. found that increased BMI, as defined by instruments for obesity 
from Mendelian Randomization, was associated with increased risks for lung squamous 
cell and small cell lung cancers but not for lung adenocarcinomas.38 These were 
consistent with our univariable MR analyses using SNPs only associated with BMI, 
which indicated a total effect for BMI on lung cancer.17 Moreover, our multivariable MR 
analyses also identified direct effects for BMI with the risk of lung adenocarcinomas and 
small cell lung cancers. Other Mendelian randomization studies for BMI and lung cancer 
also identified evidence of an increased risk for overall lung cancer39, lung squamous 
cell carcinoma39, 40, and small cell lung cancer40, as well as evidence of a decreased 
risk for lung adenocarcinoma41. However, these analyses have not jointly considered 
modeling smoking with BMI, and we have seen that there are complex relationships 
among these factors, such that both need to be jointly modeled. 
Smoking behavior is a confounder when evaluating the association between BMI and 
lung cancer. Previous MR study confirmed the role of obesity in smoking behaviors.9 By 
using multivariable MR, we removed bias caused by smoking phenotypes compared to 
using univariable MR. In the bidirectional analysis, we found that there was a much 
stronger path from BMI to smoking phenotypes rather than from smoking phenotypes to 
BMI, which indicates the role of smoking as a potential mediator between BMI and lung 
cancer risk. On the other hand, the effects of smoking (such as smoking cessation and 
cigarettes per day) on BMI were also observed. These results implied complicated 
effects of BMI and smoking behaviors on lung cancer risk. Further analyses such as 
network Mendelian randomization, which uses genetic instruments to investigate 
mediation in causal pathways, may provide insights into the causal relationships.42 
The possible mechanism between obesity and lung cancer has been investigated in 
previous studies.43 Adipokines, which are secreted by adipose tissue, have properties 
affecting carcinogenesis, immunomodulation, appetite and energy homeostasis 
regulation, and variations in levels have been associated with tumor susceptibility and 
pathogenesis44, 45. In particular, leptin seems to mediate and maintain chronic 
inflammation after exposure to inhaled antigens (e.g., smoke particles) and induce lung 
carcinogenesis46. In addition, after adding recombinant human leptin, cell proliferation 
was observed in SQ-5 human clonal squamous lung cancer derived cell lines47. 
Adiponectin, unlike leptin, correlates inversely with body weight and is considered a 
protective hormone that exerts anti-inflammatory effects. Petridou et al.48 demonstrated 
the expression of adiponectin receptors exclusively in lung cancer tissues, which 
supports the hypothesis that adiponectin mediates lung cancer development. 
Nevertheless, the role of obesity in lung carcinogenesis remains unclear and 
inconclusive. As obesity may influence different histological subtypes of lung cancer, 
further research is warranted to elucidate the role of obesity in lung cancer. 
Although two sample Mendelian Randomization is a powerful approach to make 
causal inference between exposures and outcome using summary statistics, we should 
be prudent with our findings because of several limitations. First, sample overlap can 
result in inflation of test results,49 but we expect little effect since there are no known 
overlaps in samples. In addition, the sample size for histological subtypes of lung 
cancer were limited, which will could lead to false negative errors (lung 
adenocarcinoma: 11,273 cases and 55,483 controls; lung squamous cell carcinoma: 
7,426 cases and 55,627 controls; small cell lung cancer: 2,664 cases and 21,444 
controls; ever-smokers lung cancer: 23,223 cases and 16,964 controls; never-smokers 
lung cancer: 2,355 cases and 7,504 controls23). Moreover, according to previous 
studies50, 51, in the situation of both exposure and outcome are binary, Wald-type 
estimators could introduce bias for causal odds ratio. The causal estimations between 
binary smoking phenotypes (such as smoking status and smoking cessation) and lung 
cancer should be evaluated carefully. Nevertheless, we believe that the impact is small 
since the estimation will be close to the true value if the sample size is large,15 and we 
also had a large number of instrumental variables. Furthermore, the BMI changes with 
age and the MR analysis was designed to estimate the lifetime effects of exposure52, 
but the genetic instruments used here were associated with BMI at a specific age 
interval, so it may impact interpretability and validity of the results. 
Taken together, we demonstrate that high BMI has direct inverse association with 
risk of lung adenocarcinoma and positive causal direct effects with small cell lung 
cancer. The total effects of BMI on lung squamous cell carcinoma and small cell lung 
cancer may be mediated by smoking phenotypes. These findings reveal heterogeneity 
of causal effects of BMI on histological subtypes of lung cancer. We expect that further 
investigations are needed to demystify the complex causal relationships between BMI, 
smoking and lung cancer. Our findings also suggest that future studies could explore 
the relevance of change BMI for evaluation risk of lung cancer. 
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Figure 1. Illustration of the total effect and direct effect of BMI on lung cancer. The direct 
effect of BMI on lung cancer is the effect BMI has on lung cancer not via any other 
exposure variables, which is equal to βXZ. The total effect of BMI on lung cancer is the 
effect of BMI on lung cancer directly plus the effect of BMI on lung cancer via smoking, 
which is equal to βXZ + αXYβYZ. 
 
Figure 2. Odds ratios (ORs) and 95% confidence intervals (CIs) for the effect of BMI 
and smoking phenotypes on lung cancer and histological subtypes estimated using 
multivariable Mendelian randomization (MR) inverse-variance weighted (IVW) 
approach. Overall: overall lung cancer; Adeno: lung adenocarcinoma; Squam: lung 
squamous cell carcinoma; Small: small cell lung cancer. Colors indicate five exposures. 
BMI, body mass index; SmkInit, smoking status; AgeSmk, age of smoking initiation; 
SmkCes, smoking cessation; CigDay, cigarettes per day. For example, there were 776 
BMI-associated SNPs been used in multivariable MR jointly with other smoking-
associated SNPs to investigate their causal effects on overall lung cancer. No 
significant effect of BMI on overall lung cancer was observed (OR = 0.95, 95% CI = 
0.87-1.03, P = 0.224). 
